Surgical issues after neoadjuvant treatment for gastric cancer

D. D'Ugo, R. Persiani, M. Zoccali, F. Cananzi, V. Vigorita, P. Mazzeo, A. Tufo, Alberto Biondi

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Gastric carcinoma is one of the most frequent malignancies in the world and its clinical behavior depends on the metastatic potential of the tumour. Particularly, lymphatic metastasis is one of the main predictor of tumour recurrence and survival and current pathologic staging systems reflect the concept that lymphatic spread is the most relevant prognostic factor in patients resected with curative intent. This is deducted by the observation that two thirds of gastric cancers in the western world present at an advanced stage, with nearly 85% of tumors accompanied by lymph node metastasis at diagnosis. To date most therapeutic efforts are directed toward individualization of therapeutic protocols, tailoring the extent of resection integrated by the administration of preoperative and post-operative treatment. The goal of such strategies is to improve prognosis towards the achievement of a curative resection (RO-resection) with minimal morbidity and mortality, with better postoperative quality of life. A brief review of literature about preoperative therapy for gastric carcinoma will be herein illustrated. The rationale and the general drawbacks of preoperative treatments will be both discussed in order to demonstrate its value in terms of safety and efficacy.

Original languageEnglish
Pages (from-to)315-319
Number of pages5
JournalEuropean Review for Medical and Pharmacological Sciences
Volume14
Issue number4
Publication statusPublished - Apr 2010

Fingerprint

Neoadjuvant Therapy
Stomach Neoplasms
Neoplasms
Stomach
Lymphatic Metastasis
Carcinoma
Therapeutics
Western World
Lymph Nodes
Quality of Life
Neoplasm Metastasis
Morbidity
Safety
Recurrence
Survival
Mortality

Keywords

  • Antiblastic therapy
  • Gastric carcinoma
  • Neoadjuvant therapy
  • Preoperative treatment

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology (medical)

Cite this

D'Ugo, D., Persiani, R., Zoccali, M., Cananzi, F., Vigorita, V., Mazzeo, P., ... Biondi, A. (2010). Surgical issues after neoadjuvant treatment for gastric cancer. European Review for Medical and Pharmacological Sciences, 14(4), 315-319.

Surgical issues after neoadjuvant treatment for gastric cancer. / D'Ugo, D.; Persiani, R.; Zoccali, M.; Cananzi, F.; Vigorita, V.; Mazzeo, P.; Tufo, A.; Biondi, Alberto.

In: European Review for Medical and Pharmacological Sciences, Vol. 14, No. 4, 04.2010, p. 315-319.

Research output: Contribution to journalArticle

D'Ugo, D, Persiani, R, Zoccali, M, Cananzi, F, Vigorita, V, Mazzeo, P, Tufo, A & Biondi, A 2010, 'Surgical issues after neoadjuvant treatment for gastric cancer', European Review for Medical and Pharmacological Sciences, vol. 14, no. 4, pp. 315-319.
D'Ugo D, Persiani R, Zoccali M, Cananzi F, Vigorita V, Mazzeo P et al. Surgical issues after neoadjuvant treatment for gastric cancer. European Review for Medical and Pharmacological Sciences. 2010 Apr;14(4):315-319.
D'Ugo, D. ; Persiani, R. ; Zoccali, M. ; Cananzi, F. ; Vigorita, V. ; Mazzeo, P. ; Tufo, A. ; Biondi, Alberto. / Surgical issues after neoadjuvant treatment for gastric cancer. In: European Review for Medical and Pharmacological Sciences. 2010 ; Vol. 14, No. 4. pp. 315-319.
@article{3340c18f103e4e06aabd106cfbe83bfc,
title = "Surgical issues after neoadjuvant treatment for gastric cancer",
abstract = "Gastric carcinoma is one of the most frequent malignancies in the world and its clinical behavior depends on the metastatic potential of the tumour. Particularly, lymphatic metastasis is one of the main predictor of tumour recurrence and survival and current pathologic staging systems reflect the concept that lymphatic spread is the most relevant prognostic factor in patients resected with curative intent. This is deducted by the observation that two thirds of gastric cancers in the western world present at an advanced stage, with nearly 85{\%} of tumors accompanied by lymph node metastasis at diagnosis. To date most therapeutic efforts are directed toward individualization of therapeutic protocols, tailoring the extent of resection integrated by the administration of preoperative and post-operative treatment. The goal of such strategies is to improve prognosis towards the achievement of a curative resection (RO-resection) with minimal morbidity and mortality, with better postoperative quality of life. A brief review of literature about preoperative therapy for gastric carcinoma will be herein illustrated. The rationale and the general drawbacks of preoperative treatments will be both discussed in order to demonstrate its value in terms of safety and efficacy.",
keywords = "Antiblastic therapy, Gastric carcinoma, Neoadjuvant therapy, Preoperative treatment",
author = "D. D'Ugo and R. Persiani and M. Zoccali and F. Cananzi and V. Vigorita and P. Mazzeo and A. Tufo and Alberto Biondi",
year = "2010",
month = "4",
language = "English",
volume = "14",
pages = "315--319",
journal = "European Review for Medical and Pharmacological Sciences",
issn = "1128-3602",
publisher = "Verduci Editore",
number = "4",

}

TY - JOUR

T1 - Surgical issues after neoadjuvant treatment for gastric cancer

AU - D'Ugo, D.

AU - Persiani, R.

AU - Zoccali, M.

AU - Cananzi, F.

AU - Vigorita, V.

AU - Mazzeo, P.

AU - Tufo, A.

AU - Biondi, Alberto

PY - 2010/4

Y1 - 2010/4

N2 - Gastric carcinoma is one of the most frequent malignancies in the world and its clinical behavior depends on the metastatic potential of the tumour. Particularly, lymphatic metastasis is one of the main predictor of tumour recurrence and survival and current pathologic staging systems reflect the concept that lymphatic spread is the most relevant prognostic factor in patients resected with curative intent. This is deducted by the observation that two thirds of gastric cancers in the western world present at an advanced stage, with nearly 85% of tumors accompanied by lymph node metastasis at diagnosis. To date most therapeutic efforts are directed toward individualization of therapeutic protocols, tailoring the extent of resection integrated by the administration of preoperative and post-operative treatment. The goal of such strategies is to improve prognosis towards the achievement of a curative resection (RO-resection) with minimal morbidity and mortality, with better postoperative quality of life. A brief review of literature about preoperative therapy for gastric carcinoma will be herein illustrated. The rationale and the general drawbacks of preoperative treatments will be both discussed in order to demonstrate its value in terms of safety and efficacy.

AB - Gastric carcinoma is one of the most frequent malignancies in the world and its clinical behavior depends on the metastatic potential of the tumour. Particularly, lymphatic metastasis is one of the main predictor of tumour recurrence and survival and current pathologic staging systems reflect the concept that lymphatic spread is the most relevant prognostic factor in patients resected with curative intent. This is deducted by the observation that two thirds of gastric cancers in the western world present at an advanced stage, with nearly 85% of tumors accompanied by lymph node metastasis at diagnosis. To date most therapeutic efforts are directed toward individualization of therapeutic protocols, tailoring the extent of resection integrated by the administration of preoperative and post-operative treatment. The goal of such strategies is to improve prognosis towards the achievement of a curative resection (RO-resection) with minimal morbidity and mortality, with better postoperative quality of life. A brief review of literature about preoperative therapy for gastric carcinoma will be herein illustrated. The rationale and the general drawbacks of preoperative treatments will be both discussed in order to demonstrate its value in terms of safety and efficacy.

KW - Antiblastic therapy

KW - Gastric carcinoma

KW - Neoadjuvant therapy

KW - Preoperative treatment

UR - http://www.scopus.com/inward/record.url?scp=77953147743&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953147743&partnerID=8YFLogxK

M3 - Article

C2 - 20496541

AN - SCOPUS:77953147743

VL - 14

SP - 315

EP - 319

JO - European Review for Medical and Pharmacological Sciences

JF - European Review for Medical and Pharmacological Sciences

SN - 1128-3602

IS - 4

ER -